These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12393801)

  • 1. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila.
    Chan HY; Warrick JM; Andriola I; Merry D; Bonini NM
    Hum Mol Genet; 2002 Nov; 11(23):2895-904. PubMed ID: 12393801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
    Sobue G
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of therapeutics for spinal and bulbar muscular atrophy (SBMA)].
    Sobue G
    Rinsho Shinkeigaku; 2003 Nov; 43(11):909-11. PubMed ID: 15152501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.
    Bott LC; Badders NM; Chen KL; Harmison GG; Bautista E; Shih CC; Katsuno M; Sobue G; Taylor JP; Dantuma NP; Fischbeck KH; Rinaldi C
    Hum Mol Genet; 2016 May; 25(10):1979-1989. PubMed ID: 26962150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy.
    Bailey CK; Andriola IF; Kampinga HH; Merry DE
    Hum Mol Genet; 2002 Mar; 11(5):515-23. PubMed ID: 11875046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA).
    Katsuno M; Tanaka F; Adachi H; Banno H; Suzuki K; Watanabe H; Sobue G
    Prog Neurobiol; 2012 Dec; 99(3):246-56. PubMed ID: 22609045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human adipose-derived mesenchymal stem cells as a new model of spinal and bulbar muscular atrophy.
    Dossena M; Bedini G; Rusmini P; Giorgetti E; Canazza A; Tosetti V; Salsano E; Sagnelli A; Mariotti C; Gellera C; Navone SE; Marfia G; Alessandri G; Corsi F; Parati EA; Pareyson D; Poletti A
    PLoS One; 2014; 9(11):e112746. PubMed ID: 25392924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis.
    Heine EM; Berger TR; Pluciennik A; Orr CR; Zboray L; Merry DE
    J Biol Chem; 2015 May; 290(20):12572-84. PubMed ID: 25795778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.
    Adachi H; Waza M; Tokui K; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
    J Neurosci; 2007 May; 27(19):5115-26. PubMed ID: 17494697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor.
    Mandrusiak LM; Beitel LK; Wang X; Scanlon TC; Chevalier-Larsen E; Merry DE; Trifiro MA
    Hum Mol Genet; 2003 Jul; 12(13):1497-506. PubMed ID: 12812978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.
    Nedelsky NB; Pennuto M; Smith RB; Palazzolo I; Moore J; Nie Z; Neale G; Taylor JP
    Neuron; 2010 Sep; 67(6):936-52. PubMed ID: 20869592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in Spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor.
    Beitel LK; Scanlon T; Gottlieb B; Trifiro MA
    Neurotox Res; 2005; 7(3):219-30. PubMed ID: 15897156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
    J Mol Med (Berl); 2006 Aug; 84(8):635-46. PubMed ID: 16741751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model.
    Doi H; Adachi H; Katsuno M; Minamiyama M; Matsumoto S; Kondo N; Miyazaki Y; Iida M; Tohnai G; Qiang Q; Tanaka F; Yanagawa T; Warabi E; Ishii T; Sobue G
    J Neurosci; 2013 May; 33(18):7710-27. PubMed ID: 23637164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy.
    Beauchemin AM; Gottlieb B; Beitel LK; Elhaji YA; Pinsky L; Trifiro MA
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):285-97. PubMed ID: 11719263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7.
    Janer A; Werner A; Takahashi-Fujigasaki J; Daret A; Fujigasaki H; Takada K; Duyckaerts C; Brice A; Dejean A; Sittler A
    Hum Mol Genet; 2010 Jan; 19(1):181-95. PubMed ID: 19843541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.
    Wyttenbach A; Carmichael J; Swartz J; Furlong RA; Narain Y; Rankin J; Rubinsztein DC
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2898-903. PubMed ID: 10717003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice.
    Abel A; Walcott J; Woods J; Duda J; Merry DE
    Hum Mol Genet; 2001 Jan; 10(2):107-16. PubMed ID: 11152658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
    Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
    J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
    J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.